PMID- 12121565
OWN - NLM
STAT- MEDLINE
DCOM- 20021010
LR  - 20190722
IS  - 0011-9059 (Print)
IS  - 0011-9059 (Linking)
VI  - 41
IP  - 7
DP  - 2002 Jul
TI  - Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.
PG  - 449-52
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a chemokine secreted by T cells which 
      is thought to play a critical role in the pathophysiology of psoriasis. The 
      monoclonal antibody, infliximab, complexes with TNF-alpha, rendering it inactive. 
      A recent clinical trial has reported the clinical benefit and safety of 
      infliximab in moderate to severe plaque psoriasis. We report a case of rapid 
      response and clinical benefit using infliximab in severe pustular psoriasis of 
      von Zumbusch.
FAU - Newland, Meggan R
AU  - Newland MR
AD  - Department of Dermatology and Cutaneous Surgery, University of Miami, 1444 NW 9th 
      Avenue, Miami, FL 33136, USA. dermatology.department@hcahealthcare.com
FAU - Weinstein, Andrew
AU  - Weinstein A
FAU - Kerdel, Francisco
AU  - Kerdel F
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Dermatologic Agents)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Dermatologic Agents/*therapeutic use
MH  - Female
MH  - Humans
MH  - Infliximab
MH  - Psoriasis/*drug therapy/pathology/physiopathology
MH  - Reaction Time/physiology
MH  - Severity of Illness Index
MH  - Time Factors
EDAT- 2002/07/18 10:00
MHDA- 2002/10/11 04:00
CRDT- 2002/07/18 10:00
PHST- 2002/07/18 10:00 [pubmed]
PHST- 2002/10/11 04:00 [medline]
PHST- 2002/07/18 10:00 [entrez]
AID - 1543 [pii]
AID - 10.1046/j.1365-4362.2002.01543.x [doi]
PST - ppublish
SO  - Int J Dermatol. 2002 Jul;41(7):449-52. doi: 10.1046/j.1365-4362.2002.01543.x.